Bruno Ohana, CTO of biologit, recently delivered an insightful presentation titled "AI for PV: Development and Governance for a Regulated Industry" at the World Drug Safety Congress Americas 2024.
There is growing interest and demand for AI and automation in pharmacovigilance, and regulatory guidance in the space is evolving. Bruno’s talk delved into the factors that are important for earning trust and increasing adoption of the much-needed benefits of AI in a regulated space. Bruno summarised his experience in building and implementing an AI platform in pharmacovigilance with four key themes:
Transparency for earning trust
Appropriate validation frameworks for AI
Risk-based adoption & oversight
Multi-stakeholder engagement
For a deeper dive into Bruno’s expert overview, please review the attached slides. Reach out to the biologit team today to learn more!
Comments